-
EP0680764
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP0680764
| EP0680764 - Stable preparation for the treatment of blood coagulation disorders, comprising an activated coagulation factor and lipid vesicles [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 05.03.2004 Database last updated on 07.10.2024 | Most recent event Tooltip | 05.03.2004 | Application deemed to be withdrawn | published on 21.04.2004 [2004/17] | Applicant(s) | For all designated states Baxter Aktiengesellschaft Industriestrasse 67 1221 Wien / AT | [1999/50] |
| Former [1995/45] | For all designated states IMMUNO Aktiengesellschaft Industriestrasse 67 A-1221 Wien / AT | Inventor(s) | 01 /
Eibl, Johann, Dr. Gustav Tschermak-G. 2 A-1180 Vienna / AT | 02 /
Schwarz, Hans-Peter Schindlergasse 32 A-1180 Vienna / AT | 03 /
Siekmann, Jürgen, Dr. Gerasdorfer Strasse 153/209 A-1210 Vienna / AT | 04 /
Turecek, Peter, Dr. Hutweidengasse 41 A-1190 Vienna / AT | [1995/45] | Representative(s) | Polz, Leo, et al Hoffmann - Eitle ATTENTION : ADDRESS INACTIVE - USE ASS-NR - CDR / DE | [N/P] |
| Former [2003/37] | Polz, Leo, Dr., et al Hoffmann Eitle Postfach 81 04 20 81904 München / DE | ||
| Former [1995/45] | Kolb, Helga, Dr. Dipl.-Chem., et al Hoffmann, Eitle & Partner, Patent-und Rechtsanwälte, Arabellastrasse 4 D-81925 München / DE | Application number, filing date | 95106821.2 | 05.05.1995 | [1995/45] | Priority number, date | DE19944416166 | 06.05.1994 Original published format: DE 4416166 | [1995/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP0680764 | Date: | 08.11.1995 | Language: | EN | [1995/45] | Type: | A3 Search report | No.: | EP0680764 | Date: | 28.01.1998 | [1998/05] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.12.1997 | Classification | IPC: | A61K38/48, C12N9/96, A61K47/24, // (A61K38/48, 38:35) | [1995/45] | CPC: |
A61K38/4846 (EP,US);
A61K38/4866 (EP,US);
A61K9/127 (EP,US);
A61P7/02 (EP);
C12N9/6424 (EP,US);
C12N9/647 (EP,US);
C12N9/96 (EP,US);
C12Y304/21006 (EP,US);
C12Y304/21021 (EP,US);
C12Y304/21069 (EP,US)
(-)
| C-Set: |
A61K38/4846, A61K2300/00 (US,EP);
A61K38/4866, A61K2300/00 (EP,US) | Designated contracting states | AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE [1995/45] | Title | German: | Stabile Präparation zur Behandlung von Störungen der Blutgerinnung, die ein aktiviertes Blutgerinnungsfaktor und Lipidvesikeln enthält | [1995/45] | English: | Stable preparation for the treatment of blood coagulation disorders, comprising an activated coagulation factor and lipid vesicles | [1995/45] | French: | Préparation stable pour le traitement des anomalies de la coagulation du sang comprenant un facteur de coagulation activé et des vésicules lipidiques | [1995/45] | Examination procedure | 17.03.1998 | Examination requested [1998/20] | 03.06.2003 | Despatch of a communication from the examining division (Time limit: M04) | 14.10.2003 | Application deemed to be withdrawn, date of legal effect [2004/17] | 18.11.2003 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2004/17] | Fees paid | Renewal fee | 27.05.1997 | Renewal fee patent year 03 | 28.05.1998 | Renewal fee patent year 04 | 25.05.1999 | Renewal fee patent year 05 | 16.05.2000 | Renewal fee patent year 06 | 20.04.2001 | Renewal fee patent year 07 | 21.05.2002 | Renewal fee patent year 08 | 26.05.2003 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]GB2129685 (NAT BIOLOG STANDARDS BOARD) [X] 1-6,12,18,20-23,25 * example 26 *; | [X]WO9102532 (UNIV KINGSTON [CA]) [X] 1-8,14,17,18,20-22 * page 11 - page 12 *; | [X]WO9003808 (LIPOSOME CO INC [US]) [X] 1,3,4,14,17-23 * the whole document *; | [XP]WO9504524 (OPPERBAS HOLDING BV [NL], et al) [XP] 1-8,14,17-25 * page 11; figure 1; claims 1-24 *; | [E]EP0680763 (IMMUNO AG [AT]) [E] 1-25 * the whole document *; | [A]WO9323074 (OKLAHOMA MED RES FOUND [US], et al) [A] 1-25 * page 6 *; | [A]EP0214737 (UNIV KINGSTON [CA]) [A] 1-25 * the whole document *; | [A]EP0159311 (IMMUNO AG [AT]) [A] 1-25 * the whole document *; | [A]GB2085729 (DAINIPPON PHARMACEUTICAL CO) [A] 1-25 * the whole document *; | [AD]US4348384 (HORIKOSHI ISAMU, et al) [AD] 1-25 * the whole document * |